Results 21 to 30 of about 34,322 (240)

Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial

Trials, 2020
Background Juvenile idiopathic arthritis (JIA)-associated uveitis is a chronic paediatric ocular inflammatory condition that can result in visual impairment.
Nisha R. Acharya, Caleb D. Ebert, Nicole K. Kelly, Travis C. Porco, Athimalaipet V. Ramanan, Benjamin F. Arnold, the ADJUST Research Group   +6 more
doaj   +1 more source

The risk of tuberculosis infection in 410 Saudipatients receiving adalimumab therapy

Annals of Saudi Medicine, 2021
BACKGROUND: Adalimumab is a fully humanized monoclonal antibody inhibitor of tumor necrosis factor-a used to treat various autoimmune disorders. Adalimumab poses a risk for tuberculosis (TB) infection, especially in countries where TB is endemic ...
Abdullah Al-Sohaim, Abdullah Saleh Bawazir, Turki Al-Turki, Eiman Omar Alsafi, Abdullah Al-Roqy, Layla Layqah, Salim Alawi Baharoone   +6 more
doaj   +1 more source

Defining a therapeutic range for adalimumab serum concentrations in the management of pediatric noninfectious uveitis, a step towards personalized treatment

Pediatric Rheumatology Online Journal, 2023
Background Adalimumab is currently considered the most efficacious anti-TNFα agent for childhood noninfectious uveitis (NIU). The objective of this study was to define a therapeutic range for adalimumab trough levels in the treatment of childhood NIU ...
Jo L. Dehoorne, Helena Groth, Emma Carlé, Ilse De Schrijver, Celine Sys, Patricia Delbeke, Elke O. Kreps, Thomas Renson, Carolien Bonroy   +8 more
doaj   +1 more source

Adalimumab Monotherapy in the Treatment of Idiopathic Multifocal Choroiditis: A Case Report

Case Reports in Ophthalmology, 2022
In this study, we report a case of multifocal choroiditis that was successfully treated with adalimumab monotherapy. A 25-year-old male presented with a history of bilateral multifocal choroiditis which was resistant to a combination of azathioprine ...
Arash Maleki, Andrew Philip, C. Stephen Foster   +2 more
doaj   +1 more source

Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study

Pharmacology Research & Perspectives, 2021
The primary objective of this randomized, double‐blind, parallel‐controlled study (from December 2016 to October 2018) was to evaluate pharmacokinetic (PK) equivalence of adalimumab biosimilar HLX03 and reference adalimumab in healthy volunteers, and to ...
Hong Zhang, Min Wu, Jixuan Sun, Xiaoxue Zhu, Cuiyun Li, Yanhua Ding, Xiaodi Zhang, Katherine Chai, Xiaojiao Li   +8 more
doaj   +1 more source

A Rare Side Effect due to TNF-Alpha Blocking Agent: Acute Pleuropericarditis with Adalimumab

Case Reports in Rheumatology, 2013
Tumor necrosis factor-alpha antagonism is an important treatment strategy in patients with rheumatoid arthritis, psoriatic arthritis, vasculitis, and ankylosing spondylitis. Adalimumab is one of the well-known tumor necrosis factor-alpha blocking agents.
Hakan Ozkan, Ahmet Seckin Cetinkaya, Tekin Yildiz, Tahsin Bozat   +3 more
doaj   +1 more source

Can adalimumab prevent from acute effects of lipopolysaccharide induced renal injury in rats? [PDF]

Acta Cirúrgica Brasileira
Purpose: Lipopolysaccharides is well-known in the acute renal injury process. It causes widespread activation of inflammatory cascades. Tumor necrosis factor (TNF)-α and interleukin (Il)-6 are essential proinflammatory cytokines that can induce the ...
Nuket Özkavruk Eliyatkın, Akif İşlek, Selim Durmaz, Fevzi Ayyıldız, Ömer Rahman   +4 more
doaj   +1 more source

Associations of Rheumatoid Arthritis Disease Activity With Frailty Over Five Years of Follow‐up

Arthritis Care &Research, EarlyView.
Objective To evaluate whether rheumatoid arthritis (RA) disease activity is associated with frailty both in cross‐section and longitudinally. Methods Participants within the Veterans Affairs Rheumatoid Arthritis (VARA) registry enrolled from 2003 to 2022 were included.
Courtney N. Loecker, Yangyuna Yang, Punyasha Roul, Aaron Baraff, Myra S. Schmaderer, Lani Zimmerman, Kaleb Michaud, Namrata Singh, Grant W. Cannon, Gary Kunkel, Ted R. Mikuls, Ariela R. Orkaby, Joshua F. Baker, Bryant R. England, Katherine D. Wysham   +14 more
wiley   +1 more source

Spatial‐hindrance‐based pro‐Adalimumab prevents anti‐idiotypic antibody interference in pharmacokinetic and therapeutic efficacy

Bioengineering & Translational Medicine
Adalimumab (Humira) represents a major advance in rheumatoid arthritis (RA) therapy. However, with long‐term administration of Adalimumab, anti‐idiotypic antibody (anti‐Id Ab) accelerates the Adalimumab clearance rate and reduces the therapeutic effect ...
Bo‐Cheng Huang, Yu‐Tung Chen, Yun‐Chi Lu, Kai‐Wen Ho, Shih‐Ting Hong, Tzu‐Yi Liao, I‐Hsuan Wu, En‐Shuo Liu, Jun‐Min Liao, Fang‐Ming Chen, Chia‐Ching Li, Chih‐Hung Chuang, Chiao‐Yun Chen, Tian‐Lu Cheng   +13 more
doaj   +1 more source

Neighborhood Socioeconomic Status and Short‐Term Functional Outcomes in Systemic Lupus Erythematosus

Arthritis Care &Research, EarlyView.
Objective Individuals with systemic lupus erythematosus (SLE) can accumulate functional status (FS) impairment. We evaluated the association between neighborhood socioeconomic disadvantage, as measured by the Area Deprivation Index (ADI), and FS in a national SLE sample.
Baljeet Rai, Jessica Fitzpatrick, Jing Li, Eric Roberts, Patricia Katz, Laura Plantinga, Gabriela Schmajuk, Jinoos Yazdany   +7 more
wiley   +1 more source